AR Cancer Research Results

AR, androgen receptor: Click to Expand ⟱
Source: HalifaxProj(suppress signaling);CGL-Driver Genes
Type: Oncogene
Androgens play an important role in the proliferation, differentiation, maintenance and function of the prostate [1]. Intriguingly, they may also be involved in the development and progression of prostate cancer. Androgen deprivation therapy can suppress hormone-naïve prostate cancer, but prostate cancer changes AR and adapts to survive under castration levels of androgen.

The prognostic significance of androgen receptor expression varies widely across different cancer types. In some cancers, high AR expression is associated with poor outcomes, while in others, it may indicate a better prognosis
High expression with poor prognosis is most common.

AR is used as a clinical biomarker for prostate therapy


Scientific Papers found: Click to Expand⟱
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP/DDIT3↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
8746- MeSA,    Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action
- in-vitro, Nor, LAPC-4 - in-vitro, Pca, LNCaP
AR↓, GSH↝, PSA↓,
8745- MeSA,    Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers
- in-vitro, Pca, LNCaP
AR↓, PSA↓, AntiCan↑, DHCR24↓,
9049- PatchO,    Inhibitory effects of patchouli alcohol on hepatocellular carcinoma growth through accumulation of oxidative stress and inactivation of androgen receptor signaling
- vitro+vivo, HCC, HepG2 - in-vivo, Liver, HUH7
ROS?, MMP↓, DNAdam↑, TumCCA↑, Apoptosis↑, P53↑, P21↑, Fas↑, FasL↑, Casp8↑, BAX↑, Casp9↑, ChemoSen↑, AR↓, TumCP↓, selectivity↑, eff↓, Snail↓, Twist↓, ICAM-1↓, VCAM-1↓, MMP9↓, EMT↓, toxicity↓, chemoP↑,
2028- PB,    Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms
- Review, Var, NA
HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP/DDIT3↑, AR↓, other?,
8989- PCorn,    Purple corn extract improves benign prostatic hyperplasia by inhibiting 5 alpha-reductase type 2 and inflammation in testosterone propionate-induced rats
- in-vivo, BPH, NA
*eff↑, *AR↓, *Apoptosis↑, *Inflam↓, *NF-kB↓, *NRF2↑, *eff↝, *5-AR↓, *toxicity↓,
5186- PEITC,    Phenethyl Isothiocyanate inhibits STAT3 activation in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
TumCP↓, TumCCA↑, STAT3↓, p‑JAK2↓, eff↓, TumCCA↑, AR↓, ROS↑,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
3341- QC,    Antioxidant Activities of Quercetin and Its Complexes for Medicinal Application
- Review, Var, NA - Review, Stroke, NA
*antiOx↑, *BioAv↑, *GSH↑, *AChE↓, *BChE↓, *H2O2↓, *lipid-P↓, *SOD↑, *SOD2↑, *Catalase↑, *GPx↑, *neuroP↑, *HO-1↑, *cardioP↑, *MDA↓, *NF-kB↓, *IKKα↓, *ROS↓, *PI3K↑, *Akt↑, *hepatoP↑, P53↑, BAX↑, IGF-1R↓, Akt↓, AR↓, TumCP↓, GSH↑, SOD↑, Catalase↑, lipid-P↓, *TNF-α↓, *Ca+2↓,
138- QC,  CUR,    Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
DNMTs↓, AR↑, MMP↓,
67- QC,  RES,    Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
cJun↑, AR↓,
70- QC,    Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, LAPC-4
PSA↓, AR↓, NKX3.1↓, HK2↓,
72- QC,  Se,    Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity
- in-vitro, Pca, PECs - in-vitro, Pca, LNCaP - in-vitro, Pca, NIH-3T3
AR↓,
82- QC,  ATG,    Arctigenin in combination with quercetin synergistically enhances the anti-proliferative effect in prostate cancer cells
- in-vitro, Pca, LNCaP
AR↓, PI3K/Akt↓, miR-21↓, STAT3↓, BAD↓, PRAS40↓, GSK‐3β↓, PSA↓, NKX3.1↑, Bax:Bcl2↑, miR-19b↓, miR-148a↓, AMPKα↓, TumCP↓, chemoPv↑, TumCMig↓,
81- QC,  EGCG,    Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea
- in-vivo, Pca, NA
COMT↓, MRP1/ABCC1↓, Ki-67↓, Bax:Bcl2↑, AR↓, Akt↓, p‑ERK↓, COMT↓, Synergy↑, chemoPv↑, BioAv↑,
79- QC,    Chemopreventive Effect of Quercetin in MNU and Testosterone Induced Prostate Cancer of Sprague-Dawley Rats
- in-vivo, Pca, NA
GSH↑, SOD↑, Catalase↑, GPx↑, GSR↑, IGF-1R↓, Akt↓, AR↓, TumCP↓, lipid-P↓, H2O2↓, Raf↓, p‑MEK↓, Bcl-2↑, Bcl-xL↑, Casp3↑, Casp8↑, Casp9↑,
75- QC,  ENZ,    Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells
- in-vitro, Pca, HEK293 - in-vitro, NA, 22Rv1 - in-vitro, NA, C4-2B
hnRNPA1↓, PSA↓, NKX3.1↓, FKBP5↓, UBE2C↓, AR-FL↓, AR-V7↑, AR↓, eff↑, TumVol↓, BioAv↓,
3078- RES,    The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment
- Review, Pca, NA
*ROS↓, ROS↑, DNAdam↑, Apoptosis↑, Hif1a↑, Casp3↑, Casp9↑, Cyt‑c↑, Dose↝, MMPs↓, MMP2↓, MMP9↓, EMT↓, E-cadherin↑, N-cadherin↓, AR↓,
3089- RES,    The Role of Resveratrol in Cancer Therapy
- Review, Var, NA
angioG↓, VEGF↓, EGFR↓, FGF↑, TumCMig↓, TumCI↓, TIMP1↑, MMP2↓, MMP9↓, NF-kB↓, Hif1a↓, PI3K↓, Akt↓, MAPK↓, EMT↓, AR↓,
3055- RES,    Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
BioAv↓, BioAv↓, Dose↑, eff↑, eff↑, Dose↑, BioAv↑, ROS↑, MMP↓, P21↑, p27/CDKN1B↑, TumCCA↑, ChemoSen↑, COX2/PTGS2↓, 5LO↓, VEGF↓, IL1↓, IL6↓, IL8↓, AR↓, PSA↓, MAPK↓, Hif1a↓, Glycolysis↓, miR-21↓, PTEN↑, Half-Life↝, *IGF-1↓, *IGFBP3↑, Half-Life↓,
3002- RosA,    Anticancer Effects of Rosemary (Rosmarinus officinalis L.) Extract and Rosemary Extract Polyphenols
- Review, Var, NA
TumCG↓, TumCP↓, TumCCA↑, ChemoSen↑, NRF2↑, PERK↑, SESN2↑, HO-1↑, cl‑Casp3↑, ROS↑, UPR↑, ER Stress↑, CHOP/DDIT3↑, HER2/EBBR2↓, ER-α36↓, PSA↓, BAX↑, AR↓, P-gp/ABCB1↓, Cyt‑c↑, HSP70/HSPA5↑, eff↑, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, cl‑PARP↑, Synergy↑,
3033- RosA,    Rosemary (Rosmarinus officinalis) Extract Modulates CHOP/GADD153 to Promote Androgen Receptor Degradation and Decreases Xenograft Tumor Growth
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP - vitro+vivo, NA, NA
ER Stress↑, selectivity↑, AR↓, TumCG↓, TumCCA↑, CHOP/DDIT3↑, PERK↓, GRP78/BiP↑, PSA↓,
4900- Sal,    Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications
- Review, BC, NA
CSCs↓, Apoptosis↑, TumAuto↑, necrosis↑, TumCP↓, TumCI↓, TumCMig↓, TumCG↓, TumMeta↓, eff↑, Bcl-2↓, cMyc↓, Snail↓, ALDH↓, Myc↓, AR↓, ROS↑, NF-kB↓, PTCH1↓, Smo↓, Gli1↓, GLI2↓, Wnt↓, mTOR↓, GSK‐3β↓, cycD1/CCND1↓, survivin↓, P21↑, p27/CDKN1B↑, CHOP/DDIT3↑, Ca+2↑, DNAdam↑, Hif1a↓, VEGF↓, angioG↓, MMP↓, ATP↓, p‑P53↑, γH2AX↑, ChemoSen↑,
3192- SFN,    Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention
- in-vitro, Pca, PC3
Sp1/3/4↓, selectivity↑, NRF2↑, HDAC↓, DNMTs↓, TumCCA↑, selectivity↑, HO-1↑, NQO1↑, CDK2↓, TumCP↓, BID↑, Smad1↑, Diablo↑, ICAD↑, Cyt‑c↑, IAP1↑, HSP27↑, *Cyt‑c↓, *IAP1↓, *HSP27↓, survivin↓, CDK4↓, VEGF↓, AR↓,
2446- SFN,  CAP,    The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor
- in-vitro, Pca, LNCaP
AR↓, Bcl-xL↓, TumCP↓, Glycolysis↓, HK2↓, PKA↓, Hif1a↓, PSA↓, ECAR↓, BioAv↑, BioAv↓, *toxicity↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, Var, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27/CDKN1B↑, COX2/PTGS2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1/SREBF1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2/PTGS2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
5078- SSE,  Rad,    Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
- Trial, Pca, NA
Half-Life↝, OS↑, Pain↓, PSA↓, GSH↓, ROS↑, selectivity↑, TumCG↓, AR↓, Dose↑, ChemoSen↑, RadioS↑,
1934- TQ,    Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species
- in-vitro, Pca, PC3 - in-vitro, Pca, C4-2B
ROS↑, GSH↓, eff↓, AR↓,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2/BIRC3↑, XIAP↓, TNF-α↓, COX2/PTGS2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, CompStab↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
4837- Uro,    Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review
- Review, Var, NA
AntiCan↑, TumCCA↑, Apoptosis↑, TumAuto↑, *BioAv↝, *BioAv↑, RAS↓, ERK↓, AR↓, TumCP↓, PI3K↓, Akt↓, NF-kB↓, COX2/PTGS2↓, IL6↓, IL1β↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, P53↑, Casp3↑, PARP↑, ROS↓, toxicity↓,
4854- Uro,    Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC)
- Review, Pca, NA
AR↓, ROS↓, Apoptosis↑, selectivity↑, Dose↑, MDA↓, SOD↑, GPx↑, ROS↑, Casp3↑, Casp9↑,
1816- VitK2,    Role of Vitamin K in Selected Malignant Neoplasms in Women
- Review, Var, NA
TumCP↓, TumMeta↓, TumAuto↑, Apoptosis↑, Apoptosis↑, Casp3↑, Casp7↑, ROS↑, AR↓, EMT↓, Wnt↓, MMP↓, Cyt‑c↑, NF-kB↓, cycD1/CCND1↓, TumCCA↓,
1839- VitK3,    Vitamin K3 derivative inhibits androgen receptor signaling in targeting aggressive prostate cancer cells
- in-vitro, Pca, NA
TumCP↓, Apoptosis↑, TumCCA↑, ROS↑, eff↓, AR↓, Trx↓, Bcl-2↓,
9128- ZYF,    Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression
- in-vitro, Pca, LNCaP
COX1?, COX2/PTGS2?, P21↑, TumCG↓, cl‑PARP↑, Casp3↑, Apoptosis↑, AR↓, STAT3↓, p‑PKCδ↓,
9127- ZYF,    Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant prostate cancer
- in-vitro, Pca, 22Rv1
AR↓, IGF-1R↓, TumCP?, PI3K↓, p‑Akt↓,
9126- ZYF,  Bical,    Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
AR↓, NKX3.1↓, PSA↓, Synergy↑,
9124- ZYF,    Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer
- in-vitro, Pca, NA
AntiCan↑, TumCG↓, eff↑, p‑Akt↓, PSA↓, HDAC↓, AR↓,

Showing Research Papers: 51 to 88 of 88
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 88

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ARE/EpRE↑, 1,   Catalase↓, 2,   Catalase↑, 2,   GPx↓, 2,   GPx↑, 2,   GSH↓, 6,   GSH↑, 2,   GSH↝, 1,   GSR↓, 1,   GSR↑, 1,   GSTs↓, 1,   H2O2↓, 1,   HO-1↓, 2,   HO-1↑, 2,   Iron↝, 1,   lipid-P?, 1,   lipid-P↓, 3,   lipid-P↑, 2,   MDA↓, 1,   NQO1↓, 1,   NQO1↑, 2,   NRF2↓, 5,   NRF2↑, 3,   NRF2↝, 1,   ROS?, 1,   ROS↓, 6,   ROS↑, 38,   ROS⇅, 2,   ROS↝, 1,   SOD↓, 2,   SOD↑, 3,   SOD2↓, 1,   Trx↓, 3,   TrxR↓, 2,   TrxR1↓, 1,   VitC↓, 1,   VitE↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

Ferritin↑, 1,   Tf↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   CDC25↓, 2,   compIII↓, 1,   EGF↓, 1,   mtDam↑, 2,   OXPHOS↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   5LO↓, 1,   ACC↑, 1,   AMPK↓, 1,   AMPK↑, 1,   ATP↓, 3,   mt-ATP↓, 1,   DHCR24↓, 1,   ECAR↓, 1,   FASN↓, 1,   Glycolysis↓, 3,   GSK‐3β↓, 5,   p‑GSK‐3β↓, 2,   HK2↓, 3,   NADPH↓, 1,   PDK1 / PDPK1↓, 1,   PDK3↑, 1,   PKM2↓, 1,   SIRT1↓, 2,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

AIF↑, 2,   APAF1↑, 2,   Apoptosis↑, 26,   Apoptosis↝, 1,   ASC↓, 1,   ASK1↑, 1,   BAD↓, 1,   BAX↑, 16,   BAX↝, 1,   Bax:Bcl2↑, 5,   Bcl-2↓, 16,   Bcl-2↑, 1,   Bcl-2↝, 1,   Bcl-xL↓, 4,   Bcl-xL↑, 1,   Bcl-xL↝, 1,   BID↑, 1,   BNIP3↑, 1,   Casp↑, 8,   Casp1↓, 1,   Casp3↑, 16,   Casp3↝, 1,   cl‑Casp3↑, 6,   Casp7↑, 2,   cl‑Casp7↑, 1,   Casp8↑, 5,   cl‑Casp8↑, 2,   Casp9↑, 7,   cl‑Casp9↑, 4,   Cyt‑c↑, 12,   Cyt‑c↝, 2,   Diablo↑, 2,   DR5↑, 5,   Fas↑, 4,   FasL↑, 2,   Ferroptosis↓, 1,   Ferroptosis↑, 1,   IAP1↓, 1,   IAP1↑, 1,   IAP2/BIRC3↑, 1,   cl‑IAP2/BIRC3↑, 1,   ICAD↓, 1,   ICAD↑, 1,   iNOS↓, 1,   Mcl-1↓, 5,   MDM2↓, 2,   p‑MDM2↓, 1,   necrosis↑, 1,   p38↑, 2,   p‑p38↑, 2,   PUMA↓, 1,   RIP3↑, 1,   survivin↓, 9,   TRAIL↑, 1,   TumCD↑, 1,   XIAP↓, 5,   YAP/TEAD↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 20,   Akt↝, 1,   p‑Akt↓, 10,   AMPKα↓, 1,   CK2↓, 3,   EGFR↓, 6,   EGFR↑, 1,   EGFR↝, 1,   ERK↓, 8,   ERK↑, 1,   p‑ERK↓, 3,   p‑ERK↑, 1,   HER2/EBBR2↓, 3,   HGF/c-Met↓, 2,   IGF-1R↓, 4,   IKKα↓, 2,   IκB↓, 1,   IκB↑, 1,   p‑IκB↓, 1,   JAK2↓, 2,   p‑JAK2↓, 1,   JNK↑, 4,   JNK↝, 1,   p‑JNK↓, 2,   p‑JNK↑, 1,   MAPK↓, 6,   MEK↑, 1,   p‑MEK↓, 1,   mTOR↓, 11,   mTOR↝, 1,   p‑mTOR↓, 2,   mTORC2↓, 1,   p‑P70S6K↓, 1,   p‑PDGFR-BB↓, 1,   PI3K↓, 13,   PI3K↑, 1,   PI3K↝, 1,   p‑PI3K↓, 1,   PI3K/Akt↓, 1,   PKA↓, 1,   p‑PKCδ↓, 1,   PRAS40↓, 1,   PTEN↓, 1,   PTEN↑, 3,   PTEN↝, 1,   Raf↓, 1,   RAS↓, 2,   RIP1↑, 1,   Sp1/3/4↓, 2,   Src↓, 1,   p‑Src↓, 1,   STAT3↓, 18,   p‑STAT3↓, 2,   p‑STAT6↓, 1,   STK11/LKB1↑, 1,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 1,   CBP↓, 1,   cJun↓, 2,   cJun↑, 1,   cMyc↓, 8,   p‑cMyc↑, 1,   DNMT1↓, 2,   DNMTs↓, 3,   EZH2↓, 2,   FOXM1↓, 4,   H3↓, 1,   H4↓, 1,   HATs↑, 1,   HDAC↓, 6,   HDAC10↑, 1,   HDAC6↓, 1,   miR-107↑, 1,   miR-139-5p↑, 1,   miR-148a↓, 1,   miR-155↓, 1,   miR-19b↓, 1,   miR-200b↑, 1,   miR-203↑, 1,   miR-205↑, 1,   miR-21↓, 5,   miR-224↓, 1,   miR-29b↑, 1,   miR-30a-5p↑, 1,   miR-330-5p↑, 1,   miR-340↓, 1,   miR-34a↓, 1,   miR-34a↑, 2,   miR-422a↑, 1,   MTA2↓, 1,   Myc↓, 3,   other?, 1,   other↝, 1,   SD↑, 1,   SOX4↓, 1,   SOX9↓, 1,   TCF-4↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 7,   p‑eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 8,   GRP78/BiP↓, 1,   GRP78/BiP↑, 3,   HSP27↑, 2,   HSP70/HSPA5↑, 2,   HSP90↓, 2,   HSPs↓, 1,   IRE1↑, 1,   NQO2↑, 1,   PERK↓, 1,   PERK↑, 1,   Proteasome↓, 2,   PSMB5↓, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3B-II↑, 1,   LC3II↑, 1,   SESN2↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair(tgid=10) ⓘ

DFF45↓, 1,   DNAdam↑, 8,   DNArepair↓, 1,   hTERT/TERT↓, 2,   NKX3.1↓, 4,   NKX3.1↑, 1,   p16↑, 1,   P53↓, 2,   P53↑, 12,   P53↝, 1,   p‑P53↓, 1,   p‑P53↑, 1,   PARP↑, 3,   cl‑PARP↑, 13,   PCNA↓, 3,   SAPK↑, 1,   Telomerase↓, 5,   TOP1↓, 2,   TOP2↓, 1,   TOP2↑, 1,   γH2AX↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   p‑CDK1↓, 1,   CDK2↓, 8,   CDK4↓, 10,   CDK4/6↓, 1,   CDK6↓, 2,   Cyc↝, 1,   CycB/CCNB1↓, 4,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 15,   cycD1/CCND1↝, 1,   cycE/CCNE↓, 5,   Ki-67↓, 4,   P21↓, 2,   P21↑, 17,   P21↝, 1,   p27/CDKN1B↓, 3,   p27/CDKN1B↑, 7,   p‑pRB↓, 1,   p‑RB1↓, 2,   TumCCA↓, 1,   TumCCA↑, 25,   UBE2C↓, 1,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD34↓, 1,   cFos↓, 1,   cFos↑, 1,   CSCs↓, 3,   FGF↑, 1,   Gli1↓, 1,   IGF-1↓, 2,   IGFBP3↑, 3,   Ki-67↓, 4,   Let-7↓, 1,   Let-7↑, 1,   mTORC1↓, 1,   NICD↓, 1,   NOTCH↓, 3,   NOTCH1↓, 3,   NOTCH1↑, 1,   PTCH1↓, 1,   Smo↓, 1,   TAZ↓, 1,   TumCG↓, 18,   TumCP?, 1,   TumCP↓, 23,   Wnt?, 1,   Wnt↓, 12,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   AEG1↑, 1,   AKR1C2↓, 1,   AntiAg↑, 2,   AP-1↓, 4,   AP-1↝, 1,   AXL↓, 1,   CA↓, 1,   Ca+2↓, 1,   Ca+2↑, 9,   cal2↓, 1,   cal2↑, 1,   Cdc42↓, 2,   E-cadherin↓, 1,   E-cadherin↑, 7,   EMT↓, 12,   EMT↑, 1,   FAK↓, 5,   p‑FAK↓, 1,   GLI2↓, 2,   hnRNPA1↓, 1,   ITGB1↓, 1,   ITGB4↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP1↓, 2,   MMP13↓, 2,   MMP16↓, 1,   MMP2↓, 10,   MMP2↝, 1,   MMP3↓, 2,   MMP7↓, 2,   MMP9↓, 13,   MMP9↑, 1,   MMPs↓, 3,   MUC1↓, 1,   MUC4↓, 1,   N-cadherin↓, 4,   PDGF↓, 2,   Rac1↓, 2,   Rho↓, 3,   ROCK1↓, 1,   Slug↓, 1,   Smad1↑, 1,   Snail↓, 4,   TGF-β↓, 3,   TIMP1↑, 2,   TIMP2↑, 1,   TumCA↓, 1,   TumCI↓, 11,   TumCMig↓, 8,   TumMeta↓, 8,   Twist↓, 3,   Tyro3↓, 1,   uPA↓, 4,   uPAR↓, 1,   Vim↓, 3,   Vim↑, 1,   Zeb1↓, 2,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 10,   β-catenin/ZEB1↝, 1,   p‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 13,   HIF-1↓, 1,   Hif1a↓, 7,   Hif1a↑, 1,   NO↓, 1,   VCAM-1↓, 1,   VEGF↓, 20,   VEGF↝, 1,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   CLDN1↓, 1,   GLUT1↓, 1,   LAT↓, 1,   MMP↓, 12,   MPT↑, 1,   NHE1↓, 1,   TRPV1↑, 1,   ZO-1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 1,   COX1?, 1,   COX2/PTGS2?, 1,   COX2/PTGS2↓, 10,   COX2/PTGS2↑, 1,   COX2/PTGS2↝, 1,   CXCR4↓, 4,   DR4↑, 1,   ICAM-1↓, 2,   IFN-γ↓, 1,   IL1↓, 2,   IL1α↓, 1,   IL1β↓, 2,   IL2↑, 2,   IL6↓, 6,   IL6↝, 1,   IL8↓, 1,   Inflam↓, 5,   IRAK1↓, 1,   MCP1/CCL2↓, 2,   MIP2↓, 1,   NF-kB↓, 26,   NF-kB↑, 1,   NF-kB↝, 1,   p‑NF-kB↓, 1,   p‑NF-kB↑, 1,   NLRP3↓, 1,   p65↓, 1,   p‑p65↓, 2,   ac‑p65↓, 1,   PD-1↓, 1,   PD-L1↓, 2,   PGE2↓, 2,   PSA↓, 29,   PSA↝, 1,   TNF-α↓, 3,   TNF-α↝, 1,   VitD↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↑, 1,   AhR↓, 1,   AR↓, 79,   AR↑, 3,   AR↝, 5,   AR-FL↓, 1,   AR-V7↑, 1,   COMT↓, 2,   CYP11A1↓, 1,   CYP17A1↓, 1,   CYP19↓, 1,   DHT↓, 1,   ER-α36↓, 1,   FKBP5↓, 1,   HSD3B↓, 1,   PPARα↓, 1,   PPARα↑, 1,   SRD5A1↑, 1,   StAR↓, 1,   testos↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 12,   BioAv↑, 10,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 16,   CompStab↑, 1,   CYP1A1↓, 1,   CYP1A2↑, 1,   Dose↑, 6,   Dose↝, 10,   Dose∅, 1,   eff↓, 4,   eff↑, 17,   eff↝, 2,   eff∅, 1,   Half-Life↓, 4,   Half-Life↝, 3,   MDR1↓, 2,   MRP1/ABCC1↓, 1,   NAT↓, 1,   P-gp/ABCB1↓, 2,   RadioS↑, 7,   selectivity↑, 13,   Synergy↑, 16,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 79,   AR↑, 3,   AR↝, 5,   ascitic↓, 1,   CEA↓, 1,   EGFR↓, 6,   EGFR↑, 1,   EGFR↝, 1,   EZH2↓, 2,   Ferritin↑, 1,   FOXM1↓, 4,   HER2/EBBR2↓, 3,   hTERT/TERT↓, 2,   IL6↓, 6,   IL6↝, 1,   Myc↓, 3,   NSE↓, 1,   PD-L1↓, 2,   PSA↓, 29,   PSA↝, 1,   VitD↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 6,   AntiTum↓, 1,   cachexia↓, 1,   cardioP↑, 1,   chemoP↑, 3,   chemoPv↑, 9,   hepatoP↑, 1,   neuroP↑, 1,   OS↑, 1,   Pain↓, 1,   Pin1↓, 1,   QoL↝, 1,   radioP↑, 1,   Risk↓, 1,   toxicity↓, 8,   toxicity↝, 2,   toxicity∅, 1,   TumVol↓, 4,   TumVol∅, 1,   TumW↓, 1,   TumW∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,   GutMicro↑, 2,  
Total Targets: 521

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx?, 1,   antiOx↑, 3,   Catalase↑, 4,   GPx↑, 3,   GSH↑, 3,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 2,   lipid-P↓, 2,   MDA↓, 3,   Nrf1↑, 1,   NRF2↑, 2,   ROS↓, 5,   SOD↑, 5,   SOD2↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

5LO↓, 2,   ALAT↓, 1,   AMPK↑, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Casp3↓, 1,   Cyt‑c↓, 1,   IAP1↓, 1,   iNOS↓, 1,   p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↑, 1,   IKKα↓, 1,   p‑JNK↓, 1,   MAPK↓, 1,   MAPK↑, 1,   PI3K↑, 1,   PKCδ↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP27↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

IGF-1↓, 1,   IGFBP3↑, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   Ca+2↝, 1,   MMP3↓, 1,   TIMP1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,   NO↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 1,   COX2/PTGS2↓, 2,   IL10↑, 1,   IL1β↓, 2,   IL6↓, 2,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 6,   NF-kB↓, 4,   PGE2↓, 1,   PGE2↑, 1,   Th1 response↓, 1,   Th2↑, 2,   TNF-α↓, 5,   β-HEX↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

5-AR↓, 1,   AChE↓, 1,   BChE↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 3,   BioAv↝, 3,   Dose↝, 2,   eff↑, 3,   eff↝, 1,   Half-Life?, 1,   Half-Life↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AR↓, 1,   AST↓, 1,   CRP↓, 1,   IL6↓, 2,   LDH↑, 1,  

Functional Outcomes(tgid=23) ⓘ

antiAll↑, 5,   AntiArt↑, 1,   AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 1,   chemoPv↑, 2,   cognitive↑, 1,   hepatoP↑, 4,   neuroP↑, 4,   Obesity↓, 1,   toxicity↓, 5,   toxicity∅, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 88

Scientific Paper Hit Count for: AR, androgen receptor
14 Curcumin
10 Quercetin
5 EGCG (Epigallocatechin Gallate)
4 Diindolylmethane
4 Luteolin
4 Resveratrol
4 Zyflamend
3 Boswellia (frankincense)
3 Capsaicin
2 Apigenin (mainly Parsley)
2 Phenethyl isothiocyanate
2 Bicalutamide
2 Genistein (soy isoflavone)
2 HydroxyTyrosol
2 Juglone
2 lambertianic acid
2 methylseleninic acid
2 Rosmarinic acid
2 Sulforaphane (mainly Broccoli)
2 Thymoquinone
2 Urolithin
1 Ashwagandha(Withaferin A)
1 Baicalein
1 Berberine
1 Benzyl isothiocyanate
1 Allyl isothiocyanate
1 Isothiocyanates
1 Boron
1 Carnosic acid
1 Celastrol
1 Chrysin
1 Propolis -bee glue
1 isoflavones
1 Ursolic acid
1 Emodin
1 Fisetin
1 Gambogic Acid
1 Vitamin D3
1 Inulin Prebiotic
1 Lactoferrin/Talactoferrin
1 Patchouli Oil (Pogostemon cablin)
1 Phenylbutyrate
1 Purple Corn / Purple Maize
1 Piperlongumine
1 Selenium
1 Arctigenin
1 enzalutamide
1 salinomycin
1 Silymarin (Milk Thistle) silibinin
1 Shikonin
1 Selenite (Sodium)
1 Radiotherapy/Radiation
1 Vitamin K2
1 VitK3,menadione
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:15  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page